Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

• Alberto S Villamil, Steven G Chrysant, +4 authors Jack Fan Zhang
• Journal of hypertension
• 2007

OBJECTIVES Aliskiren is a novel, orally active renin inhibitor. Its antihypertensive efficacy and safety, alone and in combination with hydrochlorothiazide (HCTZ), were investigated in an 8-week,… (More)

The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study.

• Steven G Chrysant, Michael R. Melino, Sulekha Karki, James H F Lee, Reinilde Heyrman
• Clinical therapeutics
• 2008

BACKGROUND Hypertension guidelines recommend the use of 2 agents having complementary mechanisms of action when >1 agent is needed to achieve blood pressure (BP) goals. OBJECTIVE The aim of this… (More)

Phase III multicenter trial comparing the efficacy of 2% dodecafluoropentane emulsion (EchoGen) and sonicated 5% human albumin (Albunex) as ultrasound contrast agents in patients with suboptimal…

• Paul Artur Grayburn, James L. Weiss, +18 authors Anthony N. Demaria
• Journal of the American College of Cardiology
• 1998

OBJECTIVES This study was performed to compare the safety and efficacy of intravenous 2% dodecafluoropentane (DDFP) emulsion (EchoGen) with that of active control (sonicated human albumin [Albunex])… (More)

Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.

• Suzanne Oparil, Daphne H. Williams, Steven G Chrysant, Thomas C. Marbury, Joel M. Neutel
• Journal of clinical hypertension
• 2001

In a multicenter, randomized, double-blind trial, the authors compared the antihypertensive efficacy of once-daily treatment with the new angiotensin II type 1 receptor blocker (ARB) olmesartan (20… (More)

Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study.

• Jay Y. Gillenwater, Robert W. Conn, +4 authors Nancy Dias
• The Journal of urology
• 1995

A total of 248 hypertensive patients 45 years old or older with benign prostatic hyperplasia (BPH) was included in this 16-week, multicenter, double-blind, placebo-controlled, parallel-group… (More)

Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide.

• Steven G Chrysant, Michael D Weber, Antonia C. Wang, Donald J Hinman
• American journal of hypertension
• 2004

BACKGROUND Most patients with hypertension require more than one agent to control blood pressure (BP). The purpose of this study was to assess the efficacy and safety of the angiotensin II receptor… (More)

Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris.

• Steven G Chrysant, Stephen P. Glasser, +7 authors R Casareto
• The American journal of cardiology
• 1993

The efficacy and safety of extended-release isosorbide mononitrate tablets were evaluated in patients with stable effort angina. In a double-blind study, 313 patients with stable effort-induced… (More)

Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension.

• Steven G Chrysant, Suzanne Oparil, Michael R. Melino, Sulekha Karki, James H F Lee, Reinilde Heyrman
• Journal of clinical hypertension
• 2009

J Clin Hypertens (Greenwich). 2009;11:475-482. (c) 2009 Wiley Periodicals, Inc.The authors report on the 44-week open-label extension of the 8-week, double-blind Combination of Olmesartan Medoxomil… (More)

New insights into the true nature of the obesity paradox and the lower cardiovascular risk.

• Steven G Chrysant, George S. Chrysant
• Journal of the American Society of Hypertension…
• 2013

Obesity is considered a major risk factor for cardiovascular disease, hypertension, and diabetes by National and International Committees. For this reason, they advocate weight loss and prevention of… (More)

Efficacy and Safety of Fasudil in Patients With Stable Angina: A Double-Blind, Placebo-Controlled, Phase 2 Trial

• Ralph M Vicari, Bernard R. Chaitman, +7 authors Udho Thadani
• Journal of the American College of Cardiology
• 2005

OBJECTIVES This study sought to evaluate the efficacy and safety of fasudil, an orally available rho kinase inhibitor, in patients with stable angina. BACKGROUND Several small,… (More)

• ‹
• 1
• 2
• 3
• 4
• 5
• ›